DSM-5’s new Autism Spectrum Disorder (ASD) diagnosis is a significant change that can lead to more individualized diagnostic approaches for people with ASD. It may increase the sensitivity and clarity of clinicians’ diagnoses as they consider the needs, symptoms, and severity of each patient.
SRI’s Tumor Glycome Laboratory has found a biomarker that identifies the most aggressive form of prostate cancer. Further study will confirm if a blood test can provide a much-needed tool to differentiate between aggressive cancer and the majority of cases which are slow-growing tumors.
SRI is taking an innovative approach that recognizes and attempts to address the emerging concept that Alzheimer’s could be a syndrome, with multiple causes and incestuously-interlocked effects.
Through twin studies, scientists understand the interplay between genetics and the environment in ways that the study of unrelated people–or even other types of siblings–is unable to do.
Bed bugs share our beds, feed on our blood at night, and they disappear by dawn, often leaving nothing more than a raised welt on our skin, a token of last night’s encounter. Why is it so hard to prevent and control them?
Traditional pharmaceutical companies simply can’t afford to spend the $1 billion or more it takes to bring a drug all the way to market when the affected population is too poor to buy the drugs, or too small to make a dent in the investment. Organizations like SRI fill the gap.
Bed bug bites can cause adverse reactions such as rashes, lesions, allergies, and psychological distress, and the pests most significantly impact the most vulnerable in our society.
Recent work in SRI's Cancer Biology Program indicates that an enzyme that regulates ATP - the cell’s fuel sensor - could hold a key to suppressing some aggressive tumors.
